Recently, Gastroenterology & Endoscopy News managing editor Sarah Tilyou sat down to discuss the American Gastroenterology Association’s new Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia with lead author Joel Rubenstein, MD, director of the Barrett’s esophagus program at the University of Michigan, in Ann Arbor.
“I hope the most important takeaway is in the management of low-grade dysplasia,” Dr. Rubenstein said. “Low-grade dysplasia is very frequently over-diagnosed, and if all patients who are diagnosed with low-grade dysplasia underwent EET, endoscopic eradication therapy, approximately two-thirds of Barrett’s patients would eventually undergo EET, which is really not necessary.”
Gaps in research remain, he said, citing a need for more data comparing endoscopic mucosal resection and endoscopic submucosal dissection, optimal surveillance timing, and pain control following EET.
Check out our coverage of Barrett’s esophagus and more guideline updates from our series Between the Guidelines.
—GEN Staff